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Abstract
Mass spectrometry analysis of the Ebola virus soluble glycoprotein sGP identified a rare post-translation modification, C-mannosylation, which
was found on tryptophan (W) 288. This modification has not been described for any other viral protein; however, many viral transmembrane
glycoproteins contain one or more of the recognition motifs (W-x-x-W). Elimination of the C-mannose on sGP did not significantly alter protein
biosynthesis, processing or structure. Furthermore, the protective effect of sGP on endothelial barrier function, currently the only known activity of
sGP, was unaltered. It is possible that C-mannosylationmay be a common post-translational modification of viral transmembrane glycoproteins where
it could play a role in particle maturation and/or entry by stabilizing the structure of these proteins. In this regard, C-mannosylation of sGP may be an
anomaly resulting from the uniquemanner inwhich this protein is generated as the product of unedited transcripts from the glycoprotein gene of Ebola.
© 2007 Elsevier Inc. All rights reserved.Keywords: C-mannosylation; Ebola; Glycoprotein; Post-translational modification; Structure–functionIntroduction
Ebola viruses (EBOV) belong to the family Filoviridae in
the order Mononegavirales. These viruses cause a severe
hemorrhagic fever, termed Ebola hemorrhagic fever (EHF),
with fatality rates as high as 90% (Feldmann et al., 2003). The
fourth gene of the EBOV genome encodes the precursors of a
soluble non-structural glycoprotein (pre-sGP) and the structural
transmembrane glycoprotein (pre-GP) (Sanchez et al., 1996;
Volchkov et al., 1995). Pre-sGP is the primary product and is
processed by signalase and furin cleavage into sGP and
Δ-peptide (Volchkova et al., 1999), both of which are secreted.
sGP has been detected in the serum of infected individuals
(Sanchez et al., 1996) and is hypothesized to play a role in the
pathogenesis of EHF (Feldmann et al., 2003). Pre-GP undergoes⁎ Corresponding author. Special Pathogens Program, National Microbiology
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doi:10.1016/j.virol.2007.06.015similar processing to yield the mature viral spike protein GP1,2,
which consists of the two disulphide-bonded cleavage fragments
GP1 and GP2 (Sanchez et al., 1998; Volchkov et al., 1998). sGP
shares the 295 N-terminal amino acids with GP1 but has a unique
28 amino acid carboxyl-terminus, whereas pre-GP is only
expressed after RNA editing (Volchkov et al., 1995). Despite the
large region of shared primary sequence, these proteins are
markedly different in their structure, with sGP forming
homodimers (Volchkova et al., 1998; Barrientos et al., 2004;
Falzarano et al., 2006), which according to the more recent
studies seem to exist in a parallel rather than an anti-parallel
orientation, and GP1,2 forming trimers (Sanchez et al., 1998).
These proteins also differ in their function; GP1,2 has been
shown to mediate virus entry (attachment and fusion) (Feldmann
et al., 2001) while sGP, besides additional yet unknown
functions, might have an anti-inflammatory role (Wahl-Jensen
et al., 2005). As part of our efforts to characterize the structure of
sGP (including co- and post-translational modifications) for
future functional studies, we recently demonstrated that in
contrast to GP1,2, which is heavily N- and O-glycosylated
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drates (Falzarano et al., 2006). Here we discuss the discovery of
a novel type of glycosylation, termed C-mannosylation, which
has yet to be identified for any viral protein. Zaire ebolavirus
(ZEBOV) sGPwas found to possess a C-mannose on tryptophan
(Trp) residue 288 (W288). A mutant sGP lacking this modifica-
tion was unaltered in its biosynthesis, processing, structure and
potential anti-inflammatory function. This raises the question as
to whether C-mannosylation of sGP has functional conse-
quences or if it is a fortuitous occurrence due to the parasitic
nature of viruses in mammalian cells.
Results
Ebola virus sGP is C-mannosylated
sGP peptide mapping by MALDI MS and HPLC-MALDI
MS was performed as previously described following trypsin
digestion (Falzarano et al., 2006). Two unmodified tryptic pep-Fig. 1. Identification of C-mannosylation on sGP by mass spectrometry. (A) A portio
non-modified m/z 2136.028 (VNPEIDTTIGEWAFWETK), 2264.112 (VNPEIDTTIG
respectively. The +162 Da shift resulting from the addition of the mannose is indic
prevent C-mannosylation does not contain a peak shift of +162 Da. Respe
(VNPEIDTTIGEWAFAETKK) are separated by 128.085 (one Lys residue). (C) MS
the fragmentation of the (277–294) VNPEIDTTIGEWAFWETK peptide are shown as
348.138 Da between the y6 and y7 ions corresponds to the 288-tryptophan residue wtides containing amino acids 288 to 291 (WAFW) were found:
T26 (VNPEIDTTIGEWAFWETK) and T26+T27 (VNPEIDT-
TIGEWAFWETKK) (Fig. 1A). The presence of a peptide with a
missed cleavage is typical when there are two adjacent cut sites
(KK) and in this case results in two peaks separated by
∼128.095 Da. Both peptides showed +162 Da adducts,
consistent with the mass of a hexose residue (162.053 Da,
Delta Mass—a database of protein post-translational modifica-
tions, http://www.abrf.org/index.cfm/dm.home). A comparison
of the relative intensities of the non-modified peptides and their
respective +162 Da adducts (Fig. 1A) suggested that approxi-
mately 60% of the peptides were modified. MALDIMS analysis
allowed all four of the fragments to be observed simultaneously,
while HPLC-MALDI MS analysis introduces an additional
retention time shift for the +162 Da modified species—they
elute∼1min earlier under the chromatographic conditions used.
This finding is consistent with the addition of a hydrophilic sugar
moiety to a hydrophobic Trp residue. The identification of this
post-translational modification was further supported by then of the MALDI/TOF MS spectrum of tryptic digests of purified sGP containing
EWAFWETKK) and C-mannosylated fragments m/z 2298.079 and 2426.169,
ated. (B) Spectrum demonstrating that the fragment of sGP-WXXA mutated to
ctive peaks of m/z 2020.988 (VNPEIDTTIGEWAFAETK) and 2149.073
/MS spectrum of C-mannosylated peptide m/z 2298. The y-series of ions from
well as the characteristic 120-Da loss from the parent peptide. The difference of
ith a mannose attached (186.079+162.053=348.132).
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mannosylation at amino acid position 288 to 291 (W-A-F-W)
of sGP, which was part of both peptides.
Final confirmation of W288 C-mannosylation was obtained
during low-energy CID MS/MS analysis of the modified
peptides. Fig. 1C shows MS/MS spectrum of the +162 Da
adducts of the T26 (VNPEIDTTIGEWAFWETK) peptide (MH+
2298). A complete series of y ions (y2 to y6) confirms that W291
is unmodified, while all y ions starting at y7 have a mass increase
of 162 Da. This is a strong indication that a mannose residue is
attached to W288. Furthermore, the characteristic 120 Da loss
(Furmanek and Hofsteenge, 2000) that occurs during CID of
mannosylated peptides was also observed (Fig. 1C). MS/MS
analysis of the second mannosylated peptide T26+ T27
(VNPEIDTTIGEWAFWETKK) (MH+ 2426) showed similar
results.
To ensure that this modification was not unique to the specific
cell line used, sGP was also purified from transfected Vero E6
and Huh7 cell lines. MALDI MS revealed a similar spectra to
that of the 293T cell derived sGP with modified peptides
indicating the presence of a mannose residue (Figs. 2A, B). This
is not unexpected as others have reported that C-mannosylation
occurs in multiple tissue types from diverse species (Krieg et al.,
1997; Doucey et al., 1998). In addition, sGP purified from
ZEBOV-infected Vero cells was shown to contain the C-
mannosylated peptide T26 following HPLC-MALDI MS (Fig.Fig. 2. C-mannosylation of sGP occurs in multiple cell lines and during virus infectio
and (B) Vero E6 cell lines showing non-modified m/z 2136 (VNPEIDTTIGEWAFWE
2298 and 2426, respectively. The addition of the mannose (+162 Da) is indicated. (C
Vero E6 cells indicating C-mannosylated peptide m/z 2298.082.2C), but in contrast to the transfected cell lines, only C-
mannosylated peptides were detected. To confirm this result, the
peak corresponding to C-mannosylated T26 was selected for
MS/MS which yielded results identical to Fig. 1C (data not
shown).
Alanine mutation of W291 prevents C-mannosylation of Ebola
virus sGP
In order to confirm C-mannosylation of W288, a mutant sGP
with an altered recognition sequence (sGP-WXXA), which has
previously been demonstrated to eliminate C-mannosylation
(Krieg et al., 1998), was created (Fig. 3A). sGP-WXXA was
expressed at similar levels to sGP and was secreted from the cell
as a homodimer with the same molecular mass as sGP (Fig. 3A),
indicating that biosynthesis, processing and transport of the
mutant was not significantly affected. Interestingly, the
mutation obviously destroyed one of the immunogenic epitopes
on sGP since monoclonal antibody Z42/3.7 was not able to
detect sGP-WXXA by western blot (Fig. 3B). A comparable
peptide mapping of sGP-WXXA by MALDI MS and HPLC-
MALDI MS resulted in the elimination of the mass shift
observed for both peptides T26 and T26+T27 derived from
wild-type sGP (Fig. 1B). All identified post-translational
modifications and disulphides bonds for sGP are summarized
in Fig. 3C.n. (A) MALDI/TOF MS spectrum of tryptic digests of purified sGP from Huh7
TK), 2264 (VNPEIDTTIGEWAFWETKK) and C-mannosylated fragments m/z
) Spectrum of fraction 28 from purified supernatant of Zaire ebolavirus-infected
Fig. 4. Effect of C-mannosylation on sGP rescue of TNF-α-treated endothelial
cells under static conditions. Human endothelial cells (HUVEC) were
equilibrated for 1 h to generate a baseline TER. TNF-α with and without sGP
or sGP-WXXA (10 μg ml−1) were added to the medium as indicated. Following
treatment, the chambers were monitored by impedance spectroscopy. There was
a significant difference (Pb0.05) between the TER of cells treated with TNF-α
alone and cells treated with TNF-α and sGP or sGP-WXXA at 900 min for sGP
(**) and 420 min for sGP-WXXA (*).
Fig. 3. Characterization of sGP and sGP-WXXA biosynthesis and structure. SDS–PAGE (10%) analysis of sGP and sGP-WXXA under reducing (R) and non-reducing
(NR) conditions using monoclonal antibodies (A) P1302H11 (1:100 dilution) and (B) Z42/3.7 (1:4000 dilution). The numbers on the left indicate molecular mass in
kDa. Lane 1, sGP-WXXA; lane 2, sGP. (C) Schematic representation of the sGP homodimer (grey) indicating known post-translational modifications, including the
site of C-mannosylation (redW) as well as N-glycosylation sites (green N) and all disulphide bonds (blue C). The location of the signal peptidase cleavage site (SP) and
the furin cleavage site (FC) is indicated, as is Δ-peptide (brown).
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role
We have recently demonstrated that sGP is able to restore the
decrease in barrier function of endothelial cells, which can be
provoked through TNF-α treatment (Wahl-Jensen et al., 2005).
This potential anti-inflammatory role of sGP is structure
dependent (Falzarano et al., 2006) and currently the only
functional test for this protein. It has been suggested that
C-mannosylation may play a role in protein folding, especially
involving folding around disulphide bonds. The location of the
C-mannosylated W288 is in close proximity to the cysteine
residue involved in one of the intermolecular disulphide bonds
(C306) important for the formation of sGP homodimers
(Barrientos et al., 2004; Falzarano et al., 2006). As observed
previously (Wahl-Jensen et al., 2005), treatment of endothelial
cells with TNF-α leads to a decrease in transendothelial re-
sistance (TER), which can be partially reversed by sGP (Fig. 4).
The same rescue effect was also observed when endothelial cells
were treated simultaneously with TNF-α and sGP-WXXA
(Fig. 4), demonstrating that the lack of C-mannosylation ofW288
did not alter this biological function of sGP, although it may still
be important for another as of yet unidentified function.
C-mannosylation could be widely distributed among viral
proteins
A search of the non-redundant NCBI RefSeq viral protein
database revealed 2323 proteins that contain the recognitionsequence W-x-x-W for C-mannosylation. Only proteins that
enter the endoplasmic reticulum are considered to have the
potential to be C-mannosylated; therefore, protein sequences
containing W-x-x-W were run through the SignalP 3.0 server in
both NN and HMMmodes to predict whether they could possess
a signal peptide. This predictive modeling gives a yes/no (NN)
or a predicted signal peptide/non-secretory protein/signal anchor
prediction (HMM). From this analysis, 373 viral proteins were
Table 1
Proteins from selected viruses that contain the C-mannosylation recognition sequence W-x-x-W and are predicted to have the potential to cross the ER membrane as
determined by SignalP 3.0 in both Neural Net (NN) and Hidden Markov Model (HMM) modes
Family Virus Protein NN HMM
dsDNA Poxviridae Myxoma virus m4.1 Yes Signal peptide
Molluscum contagiosum virus MC011L Yes Signal peptide
Herpesviridae Human herpesvirus 1 Virion glycoprotein M No Signal anchor
Human herpesvirus 2 Virion glycoprotein M No Signal anchor
Tegument protein No Signal peptide
Hepadnaviridae Hepatitis B virus S protein Yes Signal peptide
RT Retroviridae Friend murine leukemia virus Envelope protein Yes Signal peptide
Human immunodeficiency gp41 Yes Signal peptide
Virus 1/2 gp160 Yes Signal peptide
Simian immunodeficiency virus env Yes Signal peptide
dsRNA Reoviridae Human rotavirus VP7 Yes Signal anchor
(-)ssRNA Bornaviridae Borna disease virus Glycoprotein Yes Signal peptide
Rhabdoviridae Vesicular stomatitis virus Glycoprotein Yes Signal peptide
Mokola virus Transmembrane glycoprotein Yes Signal peptide
Filoviridae Cote d'Ivoire ebolavirus Secreted glycoprotein Yes Signal peptide
Structural glycoprotein Yes Signal peptide
Reston ebolavirus Small/secreted non-structural glycoprotein Yes Signal peptide
Structural glycoprotein Yes Signal peptide
Sudan ebolavirus Secreted glycoprotein Yes Signal peptide
Structural glycoprotein Yes Signal peptide
Zaire ebolavirus sGP Yes Signal peptide
ssGP Yes Signal peptide
Virion spike glycoprotein precursor Yes Signal peptide
Orthomyxoviridae Influenza A virus (A/New York/392/2004 (H3N2)) Hemagglutinin Yes Signal peptide
Influenza C virus CM2 protein Yes Signal peptide
Bunyaviridae Crimean–Congo hemorrhagic fever virus Glycoprotein precursor Yes Signal peptide
(+)ssRNA Coronaviridae Human coronavirus 229E Surface glycoprotein Yes Signal peptide
4a protein Yes Signal peptide
Membrane protein Yes Non-secretory
Murine hepatitis virus E1 glycoprotein No Signal anchor
E2 glycoprotein precursor Yes Signal peptide
Spike glycoprotein S Yes Signal peptide
Membrane protein M Yes Signal anchor
SARS coronavirus E2 glycoprotein precursor Yes Signal peptide
Matrix protein Yes Signal anchor
Flaviviradae Dengue virus type 1 Non-structural protein 2B Yes Signal anchor
West Nile virus Polyprotein precursor No Signal peptide
Hepatitis C virus NS2 protein Yes Signal anchor
Togaviridae Ross River virus 6K protein No Signal anchor
Rubella virus Glycoprotein E1 No Signal peptide
Parvoviridae Canine parvovirus Polyprotein No Signal peptide
NN predicts the presence/absence of a signal peptide (yes/no). HMM predicts the presence of a signal peptide/signal anchor or the lack thereof (non-secretory). The
viruses are grouped according to the guidelines of the International Committee on Taxonomy of Viruses (ICTV).
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the potential to be C-mannosylated. Among these, EBOV GP1,2
contains 3 potential C-mannosylation sites, which are highly
conserved in all 4 EBOV species, including one in the same
position as sGP, due to the similarity in the primary sequence of
the two proteins (see introduction and Feldmann et al., 2001).
Further candidate proteins for C-mannosylation can be found
among RNA viruses and include the single transmembrane
proteins vesicular stomatitis virus (VSV) G, Borna disease virus
(BDV) G and Crimean–Congo hemorrhagic fever virus (CCHF)
GC, the hemagglutinin and M2 proteins of influenza virus, the
E2 protein of SARS-coronavirus, the spike proteins of other
human coronaviruses and the envelope proteins of human
immunodeficiency virus (HIV)-1 and 2 (Table 1). Thismodification may also be present in glycoproteins of DNA
viruses including Hepatitis B virus, Myxoma virus and nume-
rous Herpesviruses.
Discussion
C-mannosylation is a relatively unknown and poorly studied
post-translation modification that has been implicated in protein
folding and/or trafficking (Furmanek and Hofsteenge, 2000).
Here we present the first identification of C-mannosylation on a
viral protein—ZEBOV sGP. Abolishment of C-mannosylation
did not significantly alter the biosynthesis, processing or release
of sGP. It also did not affect its anti-inflammatory function but
may impact on another as of yet unidentified sGP function.
88 D. Falzarano et al. / Virology 368 (2007) 83–90C-mannosylation involves the covalent attachment of an
α-mannopyranosyl residue to the indole C2 carbon atom of Trp
via a C–C linkage (Hofsteenge et al., 1994). This modification
was first described for W7 of human RNase 2 (Hofsteenge et al.,
1994). C-mannosylation has been shown to be part of the normal
biosynthetic pathway in Caenorhabditis elegans, amphibians,
birds and mammals but does not appear to occur in insect, plant,
yeast or bacterial cells (Doucey et al., 1998; Krieg et al., 1997).
The linear recognition sequence consists of W-x-x-W/F, in
which the first Trp residue becomes mannosylated (Doucey
et al., 1998). Replacement of the second Trp with a Phe residue
reduces the efficiency of C-mannosylation 3.5-fold (Krieg et al.,
1998). The C-mannosylation synthesis pathway, which appears
to be enzymatically catalyzed by proteins present in liver
microsomes (Doucey et al., 1998; Krieg et al., 1998), has been
dissected and is as follows: Mannose (Man)→→GDP-
Man→Dolichylphosphate-Man (Dol-P-Man)→ (C2-Man-Trp)
(Doucey et al., 1998).
A number of different cellular proteins have been identified as
having C-mannosylated Trp residues with some of these proteins
containing multiple modifications (Hofsteenge et al., 2001).
Proteins that contain C-mannosylation serve a variety of cellular
functions and include extracellular matrix proteins, axonal
guidance proteins, proteins involved in angiogenesis, metallo-
proteases and a number of proteins from the complement system,
including properdin and the terminal complement components
C6 to C9. It appears that for RNase2, as well as the six
polypeptides from the complement system, the hydrophilic
mannose residue fills a cavity formed by the main and side chain
atoms of a loop on an exposed region of the protein, thus playing
a structural role (Mosimann et al., 1996). It has also been
suggested that the C-mannose may be involved in protein
transport asmutations in theW-x-x-Wmotif of the erythropoietin
receptor andMP20 (a bovine lens protein that is C-mannosylated
at W43 and W61) stall the transport of these proteins in the ER-
Golgi interface or the ER, respectively (Hilton et al., 1996; Perez-
Vilar et al., 2004). Other studies have identified that mutagenesis
of the Trp residues in theW-x-x-Wmotif abolishes the binding of
the ligand for the IL-2 receptor (Miyazaki et al., 1991).
The discovery of protein C-mannosylation in a viral protein is
of interest. In many cases, post-translational modifications are
essential for the function and/or regulation of a given protein.
Previous work has shown that sGP was able to reverse the
permeability increasing effect of TNF-α on endothelial cells and
partially restore endothelial barrier function (Wahl-Jensen et al.,
2005). This finally provided us with a functional assay system
for sGP that was recently used to demonstrate that the activity of
sGP is critically dependent on its structure as maintained by
correct intermolecular disulphide bonding (Falzarano et al.,
2006). Here we introduced a point mutation into sGP that is
sufficient to abolish C-mannosylation and thus may alter the
structure of sGP. However, our investigations did not reveal
changes in the biosynthesis, transport, structure or function of
the mutant sGP-WXXA compared to wild-type sGP (Figs. 3 and
4). Moreover, the potential anti-inflammatory effect of sGP
(Wahl-Jensen et al., 2005) might not be the sole function, as it
has been suggested by others that sGPmay play a role in immuneevasion by acting as a decoy molecule for EBOV-specific
humoral immune responses or bind to neutrophils and subse-
quently inhibit their activation (Ito et al., 2001; Yang et al.,
1998). Unfortunately, these proposed functions have been
difficult to prove directly.
The vast majority of the viral proteins that contain aW-x-x-W
motif and have the potential to be C-mannosylated are surface
glycoproteins (Table 1). With this in mind, the modification of
sGP may be an anomaly resulting from the unique manner in
which this protein is generated as the product of unedited
transcripts from the glycoprotein gene of EBOV (Feldmann
et al., 2001). While not excluding a role of C-mannosylation on
sGP function, it could be that C-mannosylation may impact on
the function of the EBOV transmembrane glycoprotein GP1,2.
This protein contains multiple potential C-mannosylation sites
with two located adjacent to the predicted transmembrane region
of GP2 and one on W288 of GP1, which is identical to the one on
sGP. The location of a C-mannose on the extracellular portion
near the membrane is not unprecedented as bovine lens protein
MP20 also contains this modification in a similar location
(Perez-Vilar et al., 2004). The location of a C-mannosylation site
just inside the transmembrane region of the BDV G and on the
extracellular portion of the VSV G may further indicate that this
modification is important for the orientation of membrane
proteins or trafficking of viral membrane proteins to the cell
surface, as has been suggested for C-mannosylated mammalian
proteins (Ervin et al., 2005; Hilton et al., 1996). Alternatively, C-
mannosylation of viral proteins could also be a chance event due
to the parasitic nature of mammalian viruses that highjack the
cellular machinery to complete their life cycle; however, we find
this unlikely.
Materials and methods
Cloning and site-directed mutagenesis
The region of the GP gene corresponding to the ZEBOV
(strain Mayinga) sGP open reading frame lacking the region
expressing the signal peptide was cloned into the pDisplay
vector (Invitrogen, Burlington, ON), which contains an endo-
genous signal peptide and an N-terminal HA-tag. Site-directed
mutagenesis was performedwith the QuikChangeII site-directed
mutagenesis kit (Stratagene, La Jolla, CA) according to the
manufacturer's instructions with specifically altered oligonu-
cleotides resulting in the W288AFW→W288AFA mutation in
sGP. The presence of the mutations was verified by sequencing
after purification of plasmid DNA using the QIAfilter Plasmid
Maxi kit (Qiagen, Mississauga, ON).
Protein expression and purification
The appropriate plasmid was transfected into low passage
293T cells, Vero E6 (both human embryonic kidney cells) and
Huh7 (human hepatoma cells) using FuGene6 (Roche Diag-
nostics, Laval, QC) (6 μl per 1 μg DNA) in OptiMEM
(Invitrogen). Seventy-two hours post-transfection, supernatant
was collected and centrifuged at 5000×g for 15 min to remove
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Centricon PL-70 (30000 MWCO) (Millipore, Cambridge, ON)
and added to an anti-HA affinity matrix (Roche Diagnostics,
Laval, QC) as per the manufacturer's instructions and rotated
overnight at 4 °C. The supernatant plus the matrix were added to
gravity flow columns and washed extensively with TNE buffer
(20 mM Tris–HCl, 100 mM NaCl, 0.1 mM EDTA) containing
Tween20 (0.05%). The HA-tagged glycoproteins were eluted
with excess HA peptide (American Peptide Company, Sunny-
vale, CA) and the HA peptide eliminated by multiple washes
with TNE buffer through an Amicon Ultra 4 (30000 MWCO)
(Millipore). The presence of the recombinant protein was
confirmed by western blot using two monoclonal antibodies
directed against ZEBOVGP (Z42/3.7 and P1302H11, courtesy of
Ayato Takada, Hokkaido University, Japan and Mavanur
Suresh, University of Alberta, respectively).
Virus infection
Vero E6 cells were infected with ZEBOV (strain Mayinga) in
the biosafety level 4 (BSL4) laboratory at the National
Microbiology Laboratory at an MOI of approximately 0.5.
Three days post-infection, the supernatant was removed and
centrifuged at 5000×g for 15 min. To remove most of the virus,
the supernatant was centrifuged at 21000 RPM in an SW-41
rotor for 30 min. The supernatant was poured off and passed
through a 0.22-μm filter. SDS was added to the supernatant to
0.5% and the sample was irradiated (2 MRad). The supernatant
was dialyzed extensively against 20 mM Tris–HCl, 500 mM
NaCl, pH 7.4 buffer (TN buffer) and then added to a
concanavalin A column (GE Healthcare). Unbound protein
was washed through with TN buffer. Bound protein was eluted
with 0.75 mM methyl-α-D-glucopyranoside in TN buffer. The
fractions were concentrated with an Amicon (Millipore) and
subjected to western blot. The appropriate fraction was then
prepared for mass spectrometry.
Mass spectrometry
Sample preparation for peptide mapping by MALDI MS and
HPLC-MALDI MS was performed as previously described
(Falzarano et al., 2006). Briefly, samples were reduced (10 mM
DTT, 65 °C, 30 min), alkylated (50 mM iodoacetamide, room
temperature, 45 min), dialyzed (7,500 MWCO, against 100 mM
ammonium bicarbonate) and digested with 1:50 trypsin/sub-
strate ratio (with or without prior deglycosylation with PNGaseF
(New England Biolabs, Pickering, ON). The resultant digests
were either spotted directly on MALDI targets with a 2,5-
dihydroxybenzoic acid matrix solution or directly injected (5 μl)
into the micro HPLC system. Both non-separated samples and
chromatographic fractions were analyzed by MS and by tandem
mass spectrometry (low-energy collision-induced dissociation
(CID), MS/MS) in the Manitoba/Sciex prototype MALDI
quadrupole/TOF (QqTOF) mass spectrometer. This instrument
provides resolving power of 10,000 full width at half maximum
(FWHM) and mass accuracy of ∼10 ppm in both MS and MS/
MS modes.Endothelial cell culture and impedance spectroscopy
Impedance spectroscopy is a highly sensitive biophysical
assay that provides a unique possibility to study the endo-
thelial barrier function. This technique determines the
transendothelial electrical resistance (TER) of a cultured
endothelial cell monolayer and predominantly reflects changes
in paracellular permeability. Human umbilical vein endothelial
cells (HUVEC) were isolated and cultured as described
elsewhere (Schnittler et al., 1990) and TER was determined
as previously described (Seebach et al., 2000). Briefly, an
alternating voltage was applied and the impedance magnitude
was measured at frequencies between 10 Hz and 1 MHz
between the electrode area of the ITO slide and a counter-
electrode. The TER was calculated from the resultant spectra.
Prior to addition of TNF-α (1 ng ml−1) (R&D Systems,
Minneapolis, MN) and sGP or sGP-WXXA (10 μg ml−1),
cells were equilibrated for 1 to 2 h to establish a baseline TER.
All electrical resistance data are presented as normalized to
baseline resistance values (TER/TER0). TER data are shown
as mean±standard error. Data were compared by unpaired
t-test. Values were considered to be statistically significant
when P was b0.05.
Viral protein database search for C-mannosylation motif
Protein sequences from the non-redundant NCBI RefSeq
viral protein database (ftp://ftp.ncbi.nih.gov/refseq/release/viral/
viral1.protein.faa.gz) were scanned for the recognition sequence
W-x-x-W. These sequences were then truncated to the N-
terminal 90 amino acid residues and run through SignalP 3.0
Server (http://www.cbs.dtu.dk/services/SignalP/) in both Neural
Net (NN) and Hidden Markov Model (HMM) modes. These
algorithms predict whether a protein is likely to contain a signal
peptide.
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